This is a study of the efficacy and safety of CMA-676 as a single agent treatment of patients with Acute Myeloid Leukemia (AML) in first relapse. Secondary objectives are to assess the duration of clinical and morphologic remissions, to assess the pharmacokinetic (PK) properties of CMA-676, and to assess possible predictors of response. This is a three part, open-label, single arm, multicycle, multicenter (approximately ten centers in the U.S.) outpatient study with a study drug infusion/oberservation period. This study will examine the effects of CMA-676 given intravenously to patients with CD33+ AML in first relapse.
Showing the most recent 10 out of 1380 publications